Pfizer (PFE)
(Real Time Quote from BATS)
$29.33 USD
-0.33 (-1.11%)
Updated Sep 20, 2024 10:20 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Income Statements
Fiscal Year end for Pfizer Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 58,496 | 100,330 | 81,288 | 41,908 | 51,750 |
Cost Of Goods | 24,954 | 34,344 | 30,821 | 8,692 | 10,219 |
Gross Profit | 33,542 | 65,986 | 50,467 | 33,216 | 41,531 |
Selling & Adminstrative & Depr. & Amort Expenses | 33,320 | 31,042 | 31,034 | 25,056 | 28,357 |
Income After Depreciation & Amortization | 222 | 34,944 | 19,433 | 8,160 | 13,174 |
Non-Operating Income | 835 | -217 | 4,878 | -663 | 4,508 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 1,058 | 34,729 | 24,311 | 7,497 | 17,682 |
Income Taxes | -1,115 | 3,328 | 1,852 | 477 | 1,384 |
Minority Interest | 39 | 35 | 45 | 36 | 29 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 2,172 | 31,401 | 22,459 | 7,021 | 16,298 |
Extras & Discontinued Operations | -15 | 6 | -434 | 2,631 | 4 |
Net Income (GAAP) | 2,119 | 31,372 | 21,980 | 9,616 | 16,273 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 6,512 | 40,008 | 24,624 | 12,937 | 19,184 |
Depreciation & Amortization (Cash Flow) | 6,290 | 5,064 | 5,191 | 4,777 | 6,010 |
Income After Depreciation & Amortization | 222 | 34,944 | 19,433 | 8,160 | 13,174 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5,709.00 | 5,733.00 | 5,708.00 | 5,632.00 | 5,675.00 |
Diluted EPS Before Non-Recurring Items | 1.84 | 6.58 | 4.42 | 2.22 | 2.95 |
Diluted Net EPS (GAAP) | 0.37 | 5.47 | 3.85 | 1.71 | 2.87 |
Fiscal Year end for Pfizer Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 13,283.00 | 14,879.00 | 14,248.00 | 13,232.00 | 12,734.00 |
Cost Of Goods | 3,300.00 | 3,379.00 | 7,562.00 | 9,269.00 | 3,237.00 |
Gross Profit | 9,983.00 | 11,500.00 | 6,686.00 | 3,963.00 | 9,497.00 |
SG&A, R&D, and Dept/Amort Expenses | 8,980.00 | 7,398.00 | 11,295.00 | 7,393.00 | 7,576.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1,003.00 | 4,102.00 | -4,609.00 | -3,430.00 | 1,921.00 |
Non-Operating Income | -1,107.00 | -680.00 | 479.00 | 79.00 | 347.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -103.00 | 3,421.00 | -4,129.00 | -3,352.00 | 2,269.00 |
Income Taxes | -134.00 | 293.00 | -795.00 | -964.00 | -71.00 |
Minority Interest | 7.00 | 8.00 | 9.00 | 6.00 | 11.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 31.00 | 3,128.00 | -3,335.00 | -2,388.00 | 2,340.00 |
Extras & Discontinued Operations | 17.00 | -5.00 | -26.00 | 12.00 | -2.00 |
Net Income (GAAP) | 41.00 | 3,115.00 | -3,369.00 | -2,382.00 | 2,327.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5,696.00 | 5,697.00 | 5,647.00 | 5,646.00 | 5,713.00 |
Diluted EPS Before Non-Recurring Items | 0.60 | 0.82 | 0.10 | -0.17 | 0.67 |
Diluted Net EPS (GAAP) | 0.01 | 0.55 | -0.59 | -0.42 | 0.41 |